|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2006-5-31
|
|
pubmed:abstractText |
Aromatase inhibitors (AIs) are now established as adjuvant therapy for early hormone receptor-positive breast cancer in postmenopausal women. Their use is sometimes extended to younger women after chemotherapy-induced amenorrhoea; we have audited this in one institution's breast unit, and we propose guidelines for use in such circumstances.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Androstadienes,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Aromatase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Receptor Modulators,
http://linkedlifedata.com/resource/pubmed/chemical/Follicle Stimulating Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Luteinizing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Triazoles,
http://linkedlifedata.com/resource/pubmed/chemical/anastrozole,
http://linkedlifedata.com/resource/pubmed/chemical/exemestane,
http://linkedlifedata.com/resource/pubmed/chemical/letrozole
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2444-7
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16735701-Adult,
pubmed-meshheading:16735701-Amenorrhea,
pubmed-meshheading:16735701-Androstadienes,
pubmed-meshheading:16735701-Antineoplastic Agents, Hormonal,
pubmed-meshheading:16735701-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16735701-Aromatase Inhibitors,
pubmed-meshheading:16735701-Breast Neoplasms,
pubmed-meshheading:16735701-Chemotherapy, Adjuvant,
pubmed-meshheading:16735701-Estrogen Receptor Modulators,
pubmed-meshheading:16735701-Female,
pubmed-meshheading:16735701-Follicle Stimulating Hormone,
pubmed-meshheading:16735701-Humans,
pubmed-meshheading:16735701-Luteinizing Hormone,
pubmed-meshheading:16735701-Middle Aged,
pubmed-meshheading:16735701-Neoplasm Staging,
pubmed-meshheading:16735701-Nitriles,
pubmed-meshheading:16735701-Ovariectomy,
pubmed-meshheading:16735701-Practice Guidelines as Topic,
pubmed-meshheading:16735701-Tamoxifen,
pubmed-meshheading:16735701-Triazoles
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
|
|
pubmed:affiliation |
Royal Marsden Hospital Institute of Cancer Research, London, United Kingdom. ian.smith@rmh.nhs.uk
|
|
pubmed:publicationType |
Journal Article
|
